PT - JOURNAL ARTICLE AU - Song, Ruixin AU - Yang, Chao AU - Wang, Jiayin AU - Li, Qianqian AU - Chen, Jing AU - Sun, Kai AU - Lv, Hongmin AU - Yang, Yankai AU - Liang, Jing AU - Ye, Qing AU - Gao, YanYing AU - Li, Jun AU - Li, Ying AU - Yan, Junqing AU - Liu, Ying AU - Wang, Tao AU - Liu, Changen AU - Wang, Fei AU - Yin, Weili AU - Xiang, Huiling TI - Immune response of primary and booster immunity of SARS-CoV-2 vaccination among patients with chronic liver disease AID - 10.1101/2022.11.12.22282242 DP - 2023 Jan 01 TA - medRxiv PG - 2022.11.12.22282242 4099 - http://medrxiv.org/content/early/2023/05/28/2022.11.12.22282242.short 4100 - http://medrxiv.org/content/early/2023/05/28/2022.11.12.22282242.full AB - Aim we examined the humoral immune response and antibody dynamics after primary and booster vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients with chronic liver disease (CLD).Methods We enrolled patients with confirmed CLD and SARS-CoV-2 vaccination primary or booster immunity. Following primary or booster immunity, serological samples were gathered to detect novel coronavirus neutralizing antibodies (nCoV NTAb) and novel coronavirus spike receptor-binding proteins (nCoV S-RBD).Results The positive rate of nCoV NTAb was 60.1% in Primary and 87.6% in Booster (P<0.001). The median level of nCoV NTAb was 11.6 AU/mL in Primary and 31.6 AU/mL in Booster (P<0.001). The positive rate of nCoV S-RBD was 70.0% in Primary and 91.2% in Booster (P<0.001). The median level of nCoV S-RBD was 21.7 AU/mL in Primary and 110.6 AU/mL in Booster (P<0.001). Compared to the antibody level of primary immunity, 21 patients in whom SARS-CoV-2 vaccine antibodies were detected after both primary and booster immunizations showed an increase of 4.4 and 5.9 times in nCoV NTAb and nCoV S-RBD, respectively.Conclusion Patients with CLD show improved humoral immune response after completing primary and booster immunity of SARS-CoV-2 vaccines, while booster immunity further improves the positive rate and antibody level of patients with CLD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTianjin Health Research Project(No：TJWJ2022XK029) and Tianjin Key Medical Discipline (Specialty) Construction Project. （ No ：TJYXZDXK-034A）Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Prior to registration, each participant provided written informed consent. The research is approved by the Ethics Committee of Tianjin Third Central Hospital in China. This research protocol adheres to the ethical guidelines outlined in the 1975 Declaration of Helsinki (Approval number:IRB 2021-027-01).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript All data produced are available online